CASSADER, Maurizio
 Distribuzione geografica
Continente #
NA - Nord America 16.419
EU - Europa 11.545
AS - Asia 8.175
SA - Sud America 541
OC - Oceania 181
AF - Africa 129
Continente sconosciuto - Info sul continente non disponibili 25
Totale 37.015
Nazione #
US - Stati Uniti d'America 15.634
CN - Cina 4.980
IT - Italia 1.925
IE - Irlanda 1.504
SE - Svezia 1.451
FR - Francia 1.075
DE - Germania 980
UA - Ucraina 895
FI - Finlandia 710
KR - Corea 643
GB - Regno Unito 625
SG - Singapore 564
JP - Giappone 555
AT - Austria 469
CA - Canada 428
PL - Polonia 412
DK - Danimarca 373
VN - Vietnam 322
MX - Messico 311
IN - India 295
ES - Italia 269
BR - Brasile 231
AU - Australia 155
RU - Federazione Russa 155
TW - Taiwan 139
HK - Hong Kong 137
TR - Turchia 127
BE - Belgio 124
NL - Olanda 105
GR - Grecia 101
PE - Perù 72
CO - Colombia 67
RO - Romania 64
ID - Indonesia 63
IR - Iran 63
CL - Cile 60
TH - Thailandia 59
PT - Portogallo 50
AR - Argentina 48
EC - Ecuador 48
CH - Svizzera 45
CZ - Repubblica Ceca 42
PH - Filippine 41
EG - Egitto 35
MY - Malesia 32
SI - Slovenia 31
IL - Israele 30
SN - Senegal 29
NO - Norvegia 25
BY - Bielorussia 24
EU - Europa 24
HU - Ungheria 21
SA - Arabia Saudita 21
NZ - Nuova Zelanda 20
GT - Guatemala 14
PK - Pakistan 13
ZA - Sudafrica 13
IQ - Iraq 12
RS - Serbia 12
LU - Lussemburgo 11
VE - Venezuela 11
QA - Qatar 10
BG - Bulgaria 9
TN - Tunisia 9
MU - Mauritius 8
SK - Slovacchia (Repubblica Slovacca) 8
LV - Lettonia 7
MM - Myanmar 7
MV - Maldive 7
AE - Emirati Arabi Uniti 6
DZ - Algeria 6
GH - Ghana 6
HN - Honduras 6
KZ - Kazakistan 6
UZ - Uzbekistan 6
AN - Antille olandesi 5
AZ - Azerbaigian 5
BD - Bangladesh 5
CR - Costa Rica 5
CV - Capo Verde 5
HR - Croazia 5
KE - Kenya 5
LB - Libano 5
BO - Bolivia 4
JO - Giordania 4
PA - Panama 4
SY - Repubblica araba siriana 4
BA - Bosnia-Erzegovina 3
IS - Islanda 3
JM - Giamaica 3
LK - Sri Lanka 3
MO - Macao, regione amministrativa speciale della Cina 3
NI - Nicaragua 3
PG - Papua Nuova Guinea 3
SV - El Salvador 3
AL - Albania 2
CD - Congo 2
EE - Estonia 2
GU - Guam 2
IM - Isola di Man 2
Totale 36.985
Città #
Beijing 1.969
Chandler 1.851
Dublin 1.490
Ann Arbor 1.238
Fairfield 828
Houston 781
Jacksonville 692
Ashburn 639
Villeurbanne 630
Wilmington 609
Princeton 579
Woodbridge 568
Redwood City 484
Medford 467
Nyköping 437
Vienna 437
Dearborn 412
Torino 372
Seattle 355
Shanghai 336
Warsaw 325
Singapore 319
Cambridge 297
Pisa 294
Dong Ket 223
Guangzhou 215
Boston 213
Nanjing 187
Hangzhou 180
Boardman 170
Ottawa 160
Tokyo 127
Fremont 125
Milan 117
Wuhan 102
Chengdu 96
Norwalk 95
Taipei 94
Pune 88
New York 85
Rome 83
Toronto 79
Chongqing 75
Hefei 71
Helsinki 66
London 64
Shenyang 64
Brussels 63
Tianjin 62
Jinan 59
San Diego 58
Verona 58
Kunming 57
Changsha 56
Phoenix 50
Turin 49
Los Angeles 48
Falls Church 47
Munich 47
Washington 47
Menlo Park 46
Istanbul 45
Lima 44
Zhengzhou 44
San Mateo 43
Seoul 43
Xian 43
Central District 41
Santiago 41
Changchun 39
Nanchang 34
Central 33
Fuzhou 33
Düsseldorf 32
Mexico City 32
Silver Spring 30
West Jordan 30
Athens 29
Duncan 29
Madrid 29
Mexico 28
Mountain View 28
Saint-hubert 28
Berlin 27
Frankfurt am Main 27
Lachine 27
São Paulo 26
Xiamen 25
Saint Petersburg 24
Chicago 23
Mumbai 23
Paris 23
Bogotá 22
Riverton 22
Sydney 22
Hong Kong 20
Montréal 20
Rochester 20
Trissino 20
Barcelona 19
Totale 21.103
Nome #
Diabetic ketoacidosis with SGLT2 inhibitors 2.151
Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. 1.463
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance 873
Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis 852
Fatty liver and chronic kidney disease: Novel mechanistic insights and therapeutic opportunities 796
Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial 730
Simple lifestyle recommendations and the outcomes of gestational diabetes. A 2×2 factorial randomized trial 677
Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. 635
Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders 546
Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. 482
Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation 413
New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease 350
Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease 294
Emerging molecular targets for the treatment of nonalcoholic fatty liver disease 281
Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution 261
Contributors to the obesity and hyperglycemia epidemics. A prospective study in a population-based cohort. 239
A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. 222
Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis 222
Dietary flavonoid intake and cardiovascular risk: a population-based cohort study 208
Predictive role of the Mediterranean diet on mortality in individuals at low cardiovascular risk: A 12-year follow-up population-based cohort study 192
Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial 187
Body fat and C-reactive protein levels in healthy non-obese men. 185
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 185
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis 185
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials 184
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 183
Changes in the gut microbiota composition during pregnancy in patients with gestational diabetes mellitus (GDM) 183
Apolipoprotein H is increased in type 2 diabetic patients with microalbuminuria. 179
In vivo oxidizability of LDL in type 2 diabetic patients in good and poor glycemic control 171
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 168
Rs12778366 single nucleotide polymorphism of Sirtuin 1 (SIRT1) and response to resveratrol supplementation in patients with type 2 diabetes mellitus. 168
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load 166
The glucoregulatory and antilipolytic actions of insulin in abdominal obesity with normal or impaired glucose tolerance: an in vivo and in vitro study. 162
High-normal blood pressure and impaired renal function. A prospective study in a population-based cohort. 160
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 158
Influence of APOH protein polymorphism on apoH levels in normal and diabetic subjects. 157
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 153
Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation 150
Serum glucose, insulin, C-peptide and plasma glucagon response to oral glucose after intravenous injection of different glucocorticoids at increasing doses in man 150
Body fat is the main predictor of fibrinogen levels in healthy non-obese men 149
Serum glucose, insulin and C-peptide response to oral glucose after intravenous administration of hydrocortisone and methylprednisolone in man 149
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 145
Incidence of diabetes mellitus, cardiovascular outcomes and mortality after a 12-month lifestyle intervention: A 9-year follow-up 145
Lipoprotein(a) in non-insulin-dependent diabetic patients with normo- and microalbuminuria 145
Characterization of the carbohydrate structures of apolipoprotein H through concanavalin A affinity chromatography. 144
Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH 144
TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. 144
Relationships between human serum resistin, inflammatory markers and insulin resistance 142
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 139
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 137
Sterol Regulatory Element-Binding Factor 2 (SREBF-2) Predicts 7-Year NAFLD Incidence and Severity of Liver Disease and Lipoprotein and Glucose Dysmetabolism. 137
The rs553668 polymorphism of ADRA2A gene predicts the worsening of fasting glucose values in a cohort of subjects without diabetes. A population-based study 137
Lipoprotein(a) and insulin treatment in non insulin dependent diabetic patients 136
Abnormal insulin sensitivity in-chronic hepatitis C virus (HCV) infection: A link with steatosis? 135
Characterization and representative structures of N-oligosaccharides bound to apolipoprotein H. 135
Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and HCV chronic hepatitis 134
Lipoprotein(a) and insulin treatment in NIDDM patients 134
Dietary habits and their relations to insulin sensitivity in non-alcoholic steatohepatitis. 133
Feedback inhibition of insulin and glucagon secretion by insulin is altered in abdominal obesity with normal or impaired glucose tolerance. 132
The microbiota composition of the offspring of patients with gestational diabetes mellitus (GDM) 131
Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? 130
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic patients with chronic hepatitis C. 129
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 125
Metabolic handling of an oral fat load in NAFLD patients. 125
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 124
Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. 124
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic CHC patients. 123
Age related changes of glucagon binding and activity in isolated rat hepatocytes. 122
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 121
Transcription factor 7-like 2 (TCF7L2) polymorphism and hyperglycemia in an adult Italian population-based cohort. 120
Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial 119
Alteration in lipid metabolism after an oral fat load in subjects with NAFLD. 117
Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression? 117
Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial 117
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 115
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 114
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 112
Effetto della terapia steroidea sul controllo glicemico nel diabete insulino-trattato: confronto Deflazacort-Prednisone. 112
Resistant hypertriglyceridemia in a patient with high plasma levels of apolipoprotein CII. 110
Apolipoprotein E polymorphism and stroke subtypes in an Italian cohort 110
Nel soggetto normale la ferritemia correla con l’HOMA. 110
The binding of apolipoprotein H (beta2-Glycoprotein I) to lipoproteins. 110
Non-alcoholic fatty liver disease from pathogenesis to management: an update. 108
Gut Microbiota as a Modulator of Cardiometabolic Risk: Mechanisms and Therapeutic Implications 108
Is left ventricular hypertrophy a low-level inflammatory state? A population-based cohort study. 107
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 106
Prevalence of undiagnosed metabolic syndrome in a population of adult asymptomatic subjects. 105
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 104
Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up 103
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 103
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 103
Adiponectin gene polymorphism modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH 102
Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? 101
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 100
Plasma Adiponectin Levels in Primary Biliary Cirrhosis: A Novel Perspective for Link Between Hypercholesterolemia and Protection Against Atherosclerosis 99
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 99
Phytosterol-Enriched Yogurt Increases LDL Affinity and Reduces CD36 Expression in Polygenic Hypercholesterolemia 98
Increased LDL-cholesterol susceptibility to oxidation contributes to oxidative damage in non alcoholic steatohepadtis (NASH). 98
Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation. 97
Apolipoprotein E allele frequencies in an Italian population: relation to age and lipid profile. 96
Totale 22.491
Categoria #
all - tutte 93.234
article - articoli 0
book - libri 0
conference - conferenze 29.428
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122.662


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.741 220 191 296 535 370 871 603 391 489 496 600 679
2020/20214.931 567 327 318 290 437 339 410 233 510 521 391 588
2021/20225.690 246 334 282 408 389 290 466 404 306 515 959 1.091
2022/20236.959 859 481 197 556 570 1.698 654 454 592 220 349 329
2023/20244.560 452 557 307 333 350 551 333 292 79 358 399 549
2024/2025142 142 0 0 0 0 0 0 0 0 0 0 0
Totale 38.312